Takeda Pharmaceutical Company Ltd
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
SYR-472 Open-label Study
Phase 3
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- Drug: SYR-472
- First Posted Date
- 2012-12-18
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Takeda
- Target Recruit Count
- 14
- Registration Number
- NCT01751360
Evaluation of the Efficacy, Safety and Tolerance of Experimental Morning-only MOVIPREP® Bowel Preparation in Comparison With Split-dose With Nocturnal Pause MOVIPREP® Bowel Preparation
Phase 3
Completed
- Conditions
- Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel.
- Interventions
- First Posted Date
- 2012-11-26
- Last Posted Date
- 2014-05-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 140
- Registration Number
- NCT01732692
Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity
Phase 1
Completed
- Conditions
- Dengue Fever
- Interventions
- Biological: TDV
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 80
- Registration Number
- NCT01728792
- Locations
- 🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Phase 3
Active, not recruiting
- Conditions
- Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1334
- Registration Number
- NCT01712490
A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322
Phase 4
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- Drug: AD-4833 30 mgDrug: AD-4833 15 mgDrug: Placebo
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Takeda
- Target Recruit Count
- 207
- Registration Number
- NCT01686711
A Safety and Efficacy Study of Ramelteon Tablets for Sublingual Administration (TAK-375SL) in the Maintenance Treatment of Bipolar 1 Disorder
Phase 3
Withdrawn
- Conditions
- Bipolar Disorder
- Interventions
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- Takeda
- Registration Number
- NCT01685151
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
- First Posted Date
- 2012-08-31
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- Takeda
- Target Recruit Count
- 535
- Registration Number
- NCT01677182
Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes
Phase 3
Terminated
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: TAK-875Drug: TAK-875 Placebo
- First Posted Date
- 2012-07-23
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- Takeda
- Target Recruit Count
- 393
- Registration Number
- NCT01647542
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 104
- Registration Number
- NCT01642602
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents
Phase 2
Completed
- Conditions
- Gastroesophageal Reflux DiseaseErosive Esophagitis
- Interventions
- Drug: PlaceboDrug: Dexlansoprazole
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 63
- Registration Number
- NCT01642615
© Copyright 2025. All Rights Reserved by MedPath